04:55 PM EDT, 08/18/2025 (MT Newswires) -- ORIC Pharmaceuticals ( ORIC ) said Monday it had appointed Kevin Brodbeck to the newly created role of chief technical officer as the company prepares for potential Phase 3 trials of ORIC-944 and enozertinib in 2026.
Brodbeck joins the oncology focused company after previously holding leadership roles at peers Deciphera Pharmaceuticals and Nektar Therapeutics, it added.